GlassScriptPhysician profile
Ramya Jayaraman
NPI 1174907968
$489.74
in general payments reported to CMS, 2019-2025
12 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $236 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.42 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.67 | 2024 | Ofev |
| Lilly USA, LLC | $66.17 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $61.08 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Eisai INC. | $50.89 | 2024-2025 | |
| Medtronic, INC. | $41.32 | 2024 | Interstim |
| Amgen INC. | $28.25 | 2024-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $23.42 | 2025 | |
| Astellas Pharma US INC | $21.73 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $20.31 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $15.80 | 2025 | Airsupra |
| Exact Sciences Corporation | $14.68 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramya Jayaraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.